ProstatID

ProstatIDTM is an AI-powered software utilizing Deep Learning and Random Forest algorithms to analyze multiparametric prostate MRI data (T2W, DWI, ADC) for computer-assisted detection and diagnosis of prostate cancer. Its purpose is to serve as a concurrent reading aid for radiologists, aiming to improve the accuracy of identifying suspicious lesions, assessing malignancy likelihood, and providing PI-RADS interpretation suggestions, thereby enhancing diagnostic performance over unassisted reads.

ProstatIDTM is a radiological computer-assisted detection (CADe) and diagnostic (CADx) software designed to aid trained radiologists in identifying, assessing, and characterizing prostate abnormalities, including cancerous lesions, from MR image data. It functions as a concurrent reading tool for physicians interpreting prostate MRI exams, particularly for high-risk screening or diagnostic imaging. The software analyzes T2-weighted (T2W), Diffusion-Weighted Imaging (DWI), and Apparent Diffusion Coefficient (ADC) MRI data—notably excluding Dynamic Contrast-Enhanced (DCE) images—using Deep Learning and Random Forest algorithms. These algorithms, trained on a substantial database of biopsy-proven normal, benign, and cancerous tissues, recognize the prostate gland and suspicious lesions, assessing their likelihood of malignancy. Delivered via a cloud-based Software as a Service (SaaS) model, ProstatID processes DICOM images from compatible MRI systems and provides outputs such as prostate volume, lesion locations and extent, malignancy likelihood scores, and a PI-RADS interpretation suggestion. Key outputs of ProstatID include colorized overlays on T2 images highlighting suspicious lesions, appended post-processed image sets, decision support scores, a suggested PI-RADS exam score, 3D renditions of suspect tissue, and a PDF summary report. Standalone performance assessments demonstrated good diagnostic accuracy (AUC of 0.710, compared to 0.629 for unassisted readers) and high detection sensitivity (80% at one false positive per patient, increasing to 98% at three). ProstatID also outperformed unassisted readers in detecting and rating cancerous lesions (Δθ = +0.169). A clinical performance study with 9 physicians and 150 cases showed that using ProstatID significantly improved the area under the ROC curve for rating true positive patients by 0.042 (from 0.629 to 0.671, p=0.0291). It also significantly improved lesion detection and classification accuracy (wAFROC figure of merit increased by 0.043, p=0.034). While ProstatID showed a trend towards improving biopsy decisions, this was not consistently statistically significant in the reported analyses.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of ProstatID, specifically its lesion detection and PI-RADS scoring, compare when analyzing MRI data from different manufacturers and field strengths (e.g., Philips 1.5T vs. Siemens 3.0T), and are there specific acquisition protocols that optimize its performance?; Given that ProstatID does not use Dynamic Contrast-Enhanced (DCE) images, what is the potential incremental diagnostic value if DCE analysis were incorporated, particularly for lesions where T2W, DWI, and ADC findings are equivocal?; The document mentions training algorithms on a 'large database of biopsy-proven examples.' What is the size and diversity (e.g., Gleason scores, lesion sizes, patient demographics) of this training dataset, and how does this affect the generalizability of the algorithm to different patient populations or rarer prostate cancer subtypes?; The reduction in unnecessary biopsies showed mixed statistical significance (p=0.590 for benign lesions, p=0.058 for cancerous). What specific factors might contribute to this variability, and how might the software's output be further refined or physician training enhanced to more consistently impact biopsy decision-making?; How does ProstatID's performance, particularly its false positive rate and sensitivity, vary across different PI-RADS categories assigned by radiologists, and could it be particularly beneficial for differentiating PI-RADS 3 lesions?